Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma ...Middle East

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class...

Hence then, the article about antengene announces the approval of first in class oral xpo1 inhibitor selinexor in south korea for the treatment of relapsed or refractory multiple myeloma and diffuse large b cell lymphoma was published today ( Sunday 01/08/2021 - 04:31 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma )

Also on site :

• Walmart’s Farmhouse Baker’s Rack Makes a ‘Cute Coffee Station’ and Offers Extra Storage for Small Kitchens
• Martha Stewart’s 12-Piece Porcelain Dinnerware Set Looks Like Heirloom China and Is Perfect for Fall Hosting
• This Popular Children’s Show Ended 24 Years Ago, and a Child Psychologist Says It’s Still One of the Best Ways To Teach Kids About Feelings